Lots of deals to report this week from New England tech and life sciences companies.
—Gloucester Pharmaceuticals of Cambridge, MA, agreed to an acquisition by Summit, NJ-based Celgene (NASDAQ: [[ticker:CELG]]). Gloucester will get $340 million in cash, plus $300 million in future milestone payments out of the deal, which is expected to close by the end of March.
—Advanced Cell Technology raised $2.77 million in financing from debt and options, an SEC filing. The Worcester, MA-based company hopes to be the first to bring embryonic stem cell technology into clinical trials.
—Waltham, MA- and Menlo Park, CA-based 5AM Ventures raised a $200 million new fund, which it plans to invest in drugs, diagnostics, materials, medical devices, and reagents.
—Mobile software startup Movik of Littleton, MA, raised $8.5 million in new equity-based financing, according to regulatory documents filed last Friday. Existing investors Highland Capital Partners and North Bridge Venture Partners participated in the round. Movik CEO Ramji Raghavan is a former general manager at Telsima, founder and former chief technology officer at Coriolis Networks, and a veteran of Digital Equipment and Cabletron.
—Waltham-based ModusLink Global Solutions (NASDAQ: [[ticker:MLNK]]), a supply chain management and e-business outsourcing provider, shelled out $30 million in cash for Boulder, CO-based e-retailer Tech For Less.
—Maine-based Hydro-Photon, developer of handheld water purification devices, raised just shy of $2 million in equity, according to regulatory filings.
—Cambridge-based drug developer Epizyme added $8 million to its Series B venture financing from New Enterprise Associates, bringing the total for the round to $40 million.
—Cambridge-based Parasol Therapeutics, an MIT spinoff developing treatments and diagnostics for influenza and other viruses, raised $3.2 million in debt and equity financing, according to
